The global nasal drug delivery systems market size is estimated to be valued at US$ 48.1 billion in 2018 and is expected to witness a CAGR of 6.3% over the forecast period (2018 – 2026).
Nasal drug delivery system is an alternative to invasive administrations and provides direct access to systemic circulation. Intranasal drug delivery is common and most preferred route of administration in treatment of allergic and non-allergic rhinitis, pain, acute treatment of migraine, and nasal congestion associated with sinusitis, common cold or rhinitis. Nasal drug delivery are mostly used in case wherein rapid onset of action is required, or to reach the site where other route of administration displays ineffective results. Nasal drug delivery is also preferred route for needle-free vaccination and systemic drug delivery. Liquid nasal preparations can be administered through inhalers, droppers, spray pumps, nebulizers or atomizers.
Major advantages of nasal drug delivery is that, the drug circumvents hepatic first-pass metabolism, leading to high bioavailability as compared to drug administered orally. On the other hand, parenteral route of administration is also inconvenient for long term therapeutic treatment. Nasal cavity being highly vascular enhances the drug absorption resulting in rapid onset of action. Moreover, ease of administration coupled with non-invasive method is driving adoption of nasal drug delivery systems, in turn propelling nasal drug delivery systems market growth.
However, limitations associated with nasal drug delivery system such as histological toxicity or lesser area of absorption as compared to orally administered drug hinders the nasal drug delivery systems market growth.
Download the PDF brochure:
The regional nasal drug delivery systems market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa by Coherent Market Insights. North America nasal drug delivery systems market is estimated to hold dominant position in 2017. The factors attributed to growth of the North America in nasal drug delivery systems market is increasing research and development by local manufacturers to develop new drug device or delivery system combination.
For instance, Impel NeuroPharma, Inc., a Seattle-based clinical stage biotechnology company, is engaged in applying its Precision Olfactory Delivery (POD) nasal drug delivery platform for drugs such as levodopa powder, insulin liquid, and olanzapine powder for the treatment of Parkinson’s disease, Alzheimer’s disease and agitation in schizophrenia and bipolar disorder, respectively.
However, Asia Pacific nasal drug delivery systems market is expected to witness rapid growth, owing to increasing prevalence of diseases, which are expected to be treated by intranasal route of drug delivery. For instance, according to Journal of Allergy and Clinical Immunology, 2017, the prevalence of asthma in developed cities of Asia Pacific such as Hong Kong, Japan, and Singapore is as high as 12.4%. Key players are targeting high patient pool in this region for further growth, which is not expected in matured markets such as North America and Europe.
Click To Reading More On Nasal Drug Delivery Systems Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154